Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aton Pharma Inc.

This article was originally published in Start Up

Executive Summary

Over the course of two decades, three leading cancer investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), Paul Marks, MD, Richard Rifkind, MD, and Victoria Richon, PhD, along with Ronald Breslow, PhD of Columbia University, have performed research with the objective to develop safer, more effective cancer treatments. Their pioneering work focused on an emerging class of anti-tumor agents-histone deacetylase (HDAC) inhibitors. Now the team of four hopes to translate lab research to drug development in Aton Pharma Inc.

You may also be interested in...

Triggering Transcription: Seemingly Inactive Genes are On, but 'Stuck in Neutral'

Interest in gene regulatory networks is white hot, encompassing topics as wide ranging as reprogramming skin cells to give them characteristics of embryonic stem cells to the successful development of HDAC inhibitors. Now a research team has shown that many important regulatory genes in adult cells aren't switched off, as had been believed. They're primed to make protein, but something is stopping transcription--possibly a set of master signals that could be modulated with small molecules.

Which Private Investors are Cashing Out?

Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.

What Entrepreneurs Want, Get, and Don't Get from VCs

What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts